ROMSEY, UK, Feb. 12, 2010 — Stratophase Ltd., a specialist in real-time chemical and biochemical measurement and detection, has secured £2.5 million (about $3.9 million) in follow-on funding from existing investor East Hill Management of Providence, R.I.
“These are exciting times for Stratophase,” said company CEO Richard Williams. “We are initiating a SpectroSens early access program in key markets and are actively seeking strategic partner organizations with the intention of leveraging this widely applicable technology into multiple end markets.”
Stratophase’s SpectroSens optical microchip technology has earned another round of funding. (Photo: Stratophase Ltd)
The company said the SpectroSens real-time monitoring technology rollout in target markets will be supported by recruitment of key staff and a move to a larger facility.
The SpectroSens optical microchip platform technology is being developed for a number of applications in process measurement and biodetection. Target applications to date include real-time in-line monitoring of pharmaceutical manufacturing (both small-molecule compounds and biopharmaceuticals), biofuel production, biodetection for security and military defense and point-of-care diagnostics. The SpectroSens system is undergoing trials by several major organizations including a top-tier multinational pharmaceutical company and the UK military.
Stratophase was spun off from the University of Southampton in England. Its SpectroSens technology measures chemical processes and detects biological targets and, according to the company, the core optical measurement technology can be realized in a large number of sensing heads.
For more information, visit: www.stratophase.com